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Received 17 June 2012; accepted 19 June 2012A 79-year-old woman, with end stage renal failure (ESRF)
due to diabetic nephropathy, presented with generalized
involuntary movements for 3 days. She had a history of
hypertension, hyperlipidemia, and gouty arthritis. Gaba-
pentin (GBP) 300 mg nocte was prescribed for her post-
herpetic neuralgia involving her right V1 dermatome. Ten
hours later, she developed generalized involuntary jerky
movements, and was also drowsy and unable to walk. She
did not take further doses of GBP. On the following 2 days,
her involuntary movements persisted but were decreasing
in severity. She presented to us on the third day. She had
a Glasgow coma scale of 15 and had high frequency multi-
focal myoclonus involving her neck, bilateral upper
extremities, and trunk. Blood tests showed random glucose
8.1 mmol/L, urea 27.4 mmol/L, creatinine 531 mmol/L,
adjusted calcium 2.15 mmol/L, phosphate 1.87 mmol/L,
and normal liver function test. Computed tomography of
the brain reviewed cerebral atrophy. Her medications
include calcium supplements, frusemide, amlodipine, iso-
sorbide mononitrate, sodium bicarbonate, and para-
cetamol. GBP level measured 67 hours later was 23 mmol/L
(reference range 70e120 mmol/L). Clonazepam was
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http://dx.doi.org/10.1016/j.jfma.2012.06.001dizziness. On the fifth day, her myoclonus completely
subsided. One month later, her renal function remained
static and myoclonus did not recur.
GBP is commonly used to control neuropathic pain and
epilepsy.1,2 Myoclonus, a sudden, brief, shock-like invol-
untary movement, can be caused by anoxic brain injury,
metabolic derangement, focal brain lesions, medications,
and viral infections.2 Myoclonus is reported in 0.1% to
12.5% of patients using GBP.2 Myoclonus is classified as
focal if only one limb is involved or multifocal if it occurs
asynchronously in at least two limbs. High frequency
myoclonus refers to twitches at more than one/minute.
GBP is cleared by the kidney and its clearance is reduced
in the elderly and patients with chronic renal failure
(CRF).3 The half life of GBP is prolonged to >20 hours in
patients with CRF as compared to 5 to 8 hours in patient
with normal renal function.3 There have been previous
case reports of GBP induced myoclonus in patients with
CRF (Table 1).2e5 GBP overdose is the most likely cause of
the myoclonus in our patient as she has never had previous
myoclonus, there was a clear temporal relationship
between myoclonus and GBP, and cessation of myoclonus
after GBP was stopped. Uremia alone was unlikely to have
been the cause, as her renal function remained static. The
dosage of GBP (300 mg) was the lowest among the re-
ported cases. We are unable to obtain GBP level immedi-
ately after the onset of mycoclonus. The persistence of
mycoclonus even when the drug level fell within the
normal range suggested that GBP-induced mycolonus may& Formosan Medical Association. All rights reserved.
Table 1 A summary of our patient and previous reported cases of gabapentin-induced myoclonus in patients with chronic
renal failure.
References Age Sex Creatinine
level (mmol/L)
GBP dosage and duration
of treatment before myoclonus
Duration of
myoclonus
Treatment
Zhang et al2 59 Male 704 3 d after stepping up from
300 mg daily to 900 mg daily
15 d Observation
Zhang et al2 56 Male 616 5 d after 600 mg daily 4 d Observation
Zhang et al2 43 Female 880 3 d after stepping up from
900 mg daily to 1600 mg daily
5 d Observation
Holtkamp M et al3 66 Male Worsened
from 116 to 236
900 mg daily for 2 y 1 d Observation
Healey et al4 47 Male 359 900 mg daily (duration of
treatment before myoclonus
not reported)
Not reported Observation
Guddati AK et al5 57 Male Worsened
from 317 to 862
900 mg daily (duration of
treatment before myoclonus
not reported)
3 d Continuous
venovenous
hemodiafiltration
Current patient 79 Female 531 300 mg for 1 d 5 d Observation
Gabapentin-induced myoclonus 661not be dose related but threshold related.3 GBP probably
lowered the threshold for myoclonus in uremia. 2e5 In
general, GBP induced myoclonus is self limited. Low-dose
benzodiazepine and renal replacement therapy5 can be
used in case of severe myoclonus.
This case highlights that 300 mg of gabapentin could
result in myoclonus in patients with CRF.
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